A Next-Generation Recombinant Guinea Pig RBPMS Antibody for Retinal Research
Advances in recombinant antibody engineering are reshaping how researchers approach experimental design, validation, and long-term reproducibility. Antibodies Inc. is expanding its recombinant portfolio with the launch of a recombinant guinea pig RBPMS antibody, offering a modern, flexible solution for retinal neuroscience applications.
Designed with consistency and multiplexing in mind, this antibody delivers the reliability researchers expect from recombinant reagents while retaining the performance of a well-established RBPMS binder.
Why Recombinant? A Better Way Forward
Recombinant antibodies offer several key advantages over traditional monoclonal or polyclonal antibodies. Because they are defined by an exact and unchanging sequence, they deliver exceptional consistency - batch after batch, year after year. This eliminates one of the most persistent challenges in research: antibody variability.
The Importance of RBPMS in Retinal Research
RBPMS (RNA Binding Protein with Multiple Splicing) has become the gold-standard marker for retinal ganglion cells (RGCs). In recent years, it has proven indispensable for studies in neurodegeneration, development, and retinal circuitry.
Guinea pigs, with their unique phylogenetic distance from other common research species, have long been valued for generating polyclonal antibodies that cooperate in multiplex designs. However, traditional guinea pig polyclonal's suffer from limitations: smaller serum volumes and lower yields compared with larger hosts like rabbits or goats.
PhosphoSolutions’ guinea pig polyclonal RBPMS antibody (1832) has been extensively cited and trusted for its specificity. Following its integration into the Antibodies Inc. portfolio, this reagent provided the foundation for a next-generation recombinant alternative.
Meet the New Recombinant Guinea Pig RBPMS Antibody
The new chimeric recombinant guinea pig RBPMS antibody combines the antigen-binding variable region of the validated mouse clone OTI3B7 with the guinea pig IgG constant region. This hybrid design maintains the precise binding performance of OTI3B7 while enabling detection with standard anti-guinea pig secondaries, making it ideal for robust and flexible multiplexing.
What Sets This Antibody Apart?
· Facilitated multiplexing: Chimeric chicken and guinea pig antibodies pair the antigen-binding region of well-validated mouse monoclonals with the constant regions of chicken IgY or guinea pig IgG. This allows the use of standard anti-chicken or anti-guinea pig secondary antibodies, opening new multiplexing combinations without cross-reactivity headaches.
· Reduced cross-reactivity: Especially when working with mouse tissues, recombinant chimeric antibodies avoid the cross-reactivity issues that often arise when using mouse primary antibodies.
· Completely animal-free production: These antibodies are produced in cultured cells under serum and protein-free conditions, making the entire process fully animal-free.
A New Standard for Reproducible, Ethical Research
The new recombinant guinea pig RBPMS antibody eliminates the limitations of traditional guinea pig polyclonal while preserving everything researchers value about the original tools. With unmatched reproducibility, thoughtful engineering, and a commitment to fully animal-free production, this antibody sets a new standard for retinal neuroscience research.
